
Vivos Therapeutics (VVOS) Stock Forecast & Price Target
Vivos Therapeutics (VVOS) Analyst Ratings
Bulls say
Vivos Therapeutics Inc has demonstrated a robust financial performance, with Q3 FY25 revenue reaching $6.8 million, representing a 76% year-over-year increase, primarily fueled by contributions from the newly integrated SCN model. The substantial surge in service revenue, which more than doubled to $4.6 million, indicates effective market penetration and enhanced demand for sleep testing and treatment centers. Furthermore, the company’s ongoing expansion efforts and positive clinical outcomes from its non-invasive treatment protocols suggest a promising trajectory for future revenue growth.
Bears say
Vivos Therapeutics Inc. has reported a year-over-year revenue decline of 9% for the first half of 2025, largely attributed to its transition towards new sleep center operations, resulting in decreased quarterly revenues and lower gross margins of 55% due to discounting and shifts in service mix. Despite a rebound in revenues in the second quarter of 2025, the overall financial health of the company remains precarious with persistent operating losses, negative cash flow, and a significant accumulated deficit. Additionally, the company faces numerous risks, including challenges in achieving projected sales growth, securing necessary capital, attracting new customers, and the ongoing uncertainty regarding profitability and sustainable growth.
This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Vivos Therapeutics (VVOS) Analyst Forecast & Price Prediction
Start investing in Vivos Therapeutics (VVOS)
Order type
Buy in
Order amount
Est. shares
0 shares